Email: cspc@cspc.cn
News
May 21, 2026
Share:
Previous: VOLUNTARY ANNOUNCEMENT - USTEKINUMAB INJECTION RECEIVES MARKETING AUTHORISATION FROM NMPA
Next: VOLUNTARY ANNOUNCEMENT - SYS6010 GRANTED ANOTHER BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ESO
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us